Skip to content

Stereotaxis STXS Restricted Cash

Restricted Cash at other companies

ClearPoint Neuro logo
ClearPoint NeuroCLPT
$923K
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$852K+598%
Neuronetics logo
NeuroneticsSTIM
$5.75M+475%
Boston Scientific logo
Boston ScientificBSX
Intuitive Surgical logo
Intuitive SurgicalISRG

Other financials

Income statement

See full
Revenue$6.3M-15.8%
Gross profit$3.8M-6.6%
Operating income-$6.0M-0.9%
Net income-$5.9M-0.7%
EPS (diluted)-$0.06+14.3%

Balance sheet

See full
Cash & equivalents$14.6M+36.7%
Total debt$5.3M-10.0%
Total equity$14.4M+399%
Total assets$54.0M+18.2%

Cash flow

See full
Operating cash flow-$3.4M-93.5%
CapEx$79.0K
Free cash flow-$3.5M

Valuation

See full
Market cap$168.11M-11.6%
Enterprise value$158.77M-15.9%
P/S5.4×-0.6×

Profitability

See full
Gross margin53.9%+0.5pp
Operating margin-71%-14.0pp
Net margin-69.5%-13.7pp
FCF margin-35.5%-2.4pp

Returns & leverage

See full
Return on equity-251.5%-29.9pp
Debt / equity0.4×-1.7×
Current ratio1.6×+0.5×

Where this comes from

Reported directly by Stereotaxis in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue.

The official record: Stereotaxis’s 10-Q, filed August 13, 2025, on SEC EDGAR. View the filing →

Ask your AI about Stereotaxis's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stereotaxis's restricted cash?
Stereotaxis (STXS) reported restricted cash of $6.97M in Q2 2025.
How has Stereotaxis's restricted cash changed year-over-year?
Stereotaxis's restricted cash increased by 1348.4% year-over-year, from $481K to $6.97M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.